Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes

This work describes a first attempt of palindromic design for dual compounds that act simultaneously on peroxisome proliferator‐activated receptor gamma (PPARg) and G‐protein‐coupled receptor 40 (GPR40) for the treatment of type 2 diabetes. The compounds were synthesized by multi‐step chemical reactions and the relative mRNA expression levels of PPARg, GPR40, and GLUT‐4 were measured in cultured C2C12 muscle cells and RIN‐m5f b‐pancreatic cells. In addition, insulin secretion and GLUT‐4 translocation were measured. Compound 2 displayed a moderate increase in the mRNA expression of PPARg and GPR40. However, the translocation of the GLUT‐4 transporter was 400% with a similar effect to pioglitazone. The in vivo effect of compound 2 was determined at 25 mg/kg single dose using a normoglycemic and non‐insulin dependent diabetes mellitus (NIDDM) rat models. Compound 2 showed basal plasma glucose in diabetic rats with feed intake, which is associated with the moderate release of insulin measured in cells. Surprisingly, the glucose does not decrease in normoglycemic rats. Compound 2 maintained significant interactions with the GPR40 and PPARg receptors during molecular dynamics. Altogether, the results demonstrate that compound 2, with a palindromic design, simultaneously activates PPARg and GPR40 receptors without inducing hypoglycemia.